Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry. Ampuero J, et al. Among authors: diago m. Clin Gastroenterol Hepatol. 2020 Jan;18(1):216-225.e5. doi: 10.1016/j.cgh.2019.05.051. Epub 2019 Jun 11. Clin Gastroenterol Hepatol. 2020. PMID: 31195161 Free article.
Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.
Lo Iacono O, Castro A, Diago M, Moreno JA, Fernandez-Bermejo M, Vega P, García V, Carbonell P, Sanz P, Borque MJ, García-Buey L, García-Monzón C, Pedreira J, Moreno-Otero R. Lo Iacono O, et al. Among authors: diago m. Aliment Pharmacol Ther. 2000 Apr;14(4):463-9. doi: 10.1046/j.1365-2036.2000.00713.x. Aliment Pharmacol Ther. 2000. PMID: 10759626
Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.
Sánchez-Tapias JM, Crespo J, Diago M, Pérez R, Romero-Gómez M, Muñoz-Sánchez M. Sánchez-Tapias JM, et al. Among authors: diago m. Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):579-84. Methods Find Exp Clin Pharmacol. 2002. PMID: 12616704 Clinical Trial.
Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy.
Apolinario A, Diago M, Lo Iacono O, Lorente R, Pérez C, Majano PL, Clemente G, García-Monzón C. Apolinario A, et al. Among authors: diago m. Aliment Pharmacol Ther. 2004 Mar 1;19(5):551-62. doi: 10.1111/j.1365-2036.2004.01872.x. Aliment Pharmacol Ther. 2004. PMID: 14987324
Serum immunological profile in patients with chronic autoimmune cholestasis.
Romero-Gómez M, Wichmann I, Crespo J, Parés A, Rodrigo L, Alvarez A, Diago M, Pons-Romero F, Sanchez-Munoz D, Aguilar-Reina J, Andrade RJ, Salmeron J, Sánchez-Pobre P, Rebollo JM, Martin-Vivaldi R, Castellano-Megias V, Nuñez-Roldan A, Bruguera M; Spanish Group for the Study of Autoimmune Cholangitis. Romero-Gómez M, et al. Among authors: diago m. Am J Gastroenterol. 2004 Nov;99(11):2150-7. doi: 10.1111/j.1572-0241.2004.40416.x. Am J Gastroenterol. 2004. PMID: 15554996
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Romero-Gómez M, et al. Among authors: diago m. Gastroenterology. 2005 Mar;128(3):636-41. doi: 10.1053/j.gastro.2004.12.049. Gastroenterology. 2005. PMID: 15765399
Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C. Diago M, et al. Gut. 2006 Mar;55(3):374-9. doi: 10.1136/gut.2005.074062. Epub 2005 Sep 8. Gut. 2006. PMID: 16150856 Free PMC article. Clinical Trial.
HLA-C and KIR genes in hepatitis C virus infection.
Montes-Cano MA, Caro-Oleas JL, Romero-Gómez M, Diago M, Andrade R, Carmona I, Aguilar Reina J, Núñez-Roldán A, González-Escribano MF. Montes-Cano MA, et al. Among authors: diago m. Hum Immunol. 2005 Nov;66(11):1106-9. doi: 10.1016/j.humimm.2006.02.001. Epub 2006 Mar 9. Hum Immunol. 2005. PMID: 16571411
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R; TeraViC-4 Study Group. Sánchez-Tapias JM, et al. Among authors: diago m. Gastroenterology. 2006 Aug;131(2):451-60. doi: 10.1053/j.gastro.2006.05.016. Gastroenterology. 2006. PMID: 16890599 Clinical Trial.
225 results